|
Journal Papers, Abstracts, and Commentaries
| |
|
Nucleotide Reverse Transcriptase Inhibitors: A Thorough
Review, Present Status and Future Perspective as HIV Therapeutics.
Holec AD, Mandal S, Prathipati PK, Destache CJ.
Curr HIV Res.
2017 Nov 19.
Abstract
Removing inactive NRTIs in a salvage regimen is safe,
maintains virological suppression and reduces treatment costs: 96 weeks post
VERITAS study.
Trottier B, Longpré
D, Dion H, et al
J Int AIDS Soc. 2014 Nov
2;17(4(Suppl 3)):19815
Abstract
FULL-TEXT ARTICLE
Antiretroviral regimens sparing agents from the nucleoside(tide) reverse
transcriptase inhibitor class: a review of the recent literature.
Achhra AC, Boyd MA.
AIDS Res Ther. 2013 Dec 13;10(1):33.
Paper
Nucleoside Reverse Transcriptase Inhibitors, Nonnucleoside
Reverse Transcriptase Inhibitors, and Protease Inhibitors in the Treatment of
HIV Infections (AIDS).
De Clercq E.
Adv Pharmacol.
2013;67:317-58.
Abstract
The Use of Nucleoside Reverse Transcriptase Inhibitors Sparing
Regimens in Treatment-Experienced HIV-1 Infected Patients.
Di Biagio A, Ricci E, Viscoli C, et al
Curr HIV Res. 2013 Feb 20..
Abstract
NRTI Backbone in HIV Treatment: Will it Remain Relevant?
Tressler R, Godfrey C.
Drugs. 2012 Nov
12;72(16):2051-62.
Abstract |
Frequent Emergence of N348I in HIV-1 Subtype C Reverse Transcriptase with
Failure of Initial Therapy
Reduces Susceptibility to Reverse Transcriptase Inhibitors.
Brehm JH, Koontz DL, Wallis
CL, et al
Clin Infect Dis. 2012 May 22
Abstract
The role of nucleoside and nucleotide analogues in nodular
regenerative hyperplasia
in HIV-infected patients: A case control study.
Cotte L, Bénet T, Billioud C, Miailhes P, et a
J Hepatol.
2010 Sep 19.
Abstract |
Development of a stochastic model for the efficacy of NRTIs using known
mechanisms of action.
Khalili S, Monaco JM, Armaou A.
J Theor Biol. 2010 May 24
Abstract |
Nucleoside and Nucleotide HIV Reverse Transcriptase Inhibitors:
25 Years After Zidovudine.
Cihlar T, Ray A.
Antiviral Res. 2009 Oct 31.
Abstract |
A review of nucleoside reverse transcriptase inhibitor use to
prevent perinatal transmission of HIV.
Nurutdinova D, Overton ET.
Expert Opin Drug Saf.
2009 Aug 29
Abstract |
Establishment of pharmacological evaluation system for non-nucleoside
reverse-transcriptase inhibitors
resistant HIV-1
Cao YL, Li SX, Chen H, Guo Y.
Yao Xue Xue Bao. 2009
Apr;44(4):355-61
Abstract |
Pharmacokinetic-pharmacodynamic relationship of NRTIs and its connection to
viral escape:
An example based on zidovudine.
von Kleist M, Huisinga W.
Eur J Pharm Sci. 2008
Dec 25.
Abstract
|
Trends in the Design of Nucleoside Analogues as Anti-HIV Drugs.
el Kouni MH.
Curr Pharm Des
2002;8(8):581-9
Abstract
|
Journal Papers, Abstracts, and Commentaries
| |
Multiscale Systems-Pharmacology Pipeline to Assess the Prophylactic Efficacy
of NRTIs Against HIV-1.
Duwal S, Sunkara V, von Kleist M.CPT
Pharmacometrics Syst Pharmacol. 2016
Jul 21.
Abstract
Rapid plasma viral suppression in naive HIV-infected patients
with high CD4 cells and low viraemia initiating a dual nucleoside reverse
transcriptase inhibitor strategy: a proof-of-concept study.
Seang S, Fourati S, Keita Y, et al:}
J Antimicrob Chemother.
2014 Jul 22.
Abstract
SAMHD1 has differential impact on the efficacies of HIV
nucleoside reverse transcriptase inhibitors.
Huber AD, Michailidis E, Schultz ML, et al
Antimicrob Agents Chemother.
2014 May 27.
Abstract
Immunovirological Response to Triple Nucleotide
Reverse-Transcriptase Inhibitors and
Ritonavir-Boosted Protease Inhibitors in Treatment-Naive
HIV-2-Infected Patients: The ACHIEV2E
Collaboration Study Group.
Benard A, van Sighem A,
Taieb A, et al
Clin Infect Dis. 2011
May;52(10):1257-1266
Abstract
FULL-TEXT ARTICLE
Long-term CD4+ T-cell count evolution after switching from
regimens including HIV nucleoside
reverse transcriptase inhibitors (NRTI) plus protease inhibitors
to regimens containing NRTI plus
non-NRTI or only NRTI containing NRTI plus non-NRTI or only NRTI.
Torti C,
d'Arminio-Monforte A, Pozniak AL, et al
BMC Infect Dis.
2011 Jan 25;11(1):23.
Paper |
Efficacy and safety of nucleoside reverse transcriptase
inhibitor-sparing salvage therapy
for multidrug-resistant HIV-1 infection based on new-class and
new-generation antiretrovirals.
Imaz A, Llibre JM, Mora M, et al
J Antimicrob Chemother.
2010 Dec 14.
Abstract |
Nucleoside reverse transcriptase inhibitors in combination therapy for HIV
patients:
systematic review and meta-analysis.
Chowers M, Gottesman BS, Leibovici
L, et al
Eur J Clin Microbiol Infect Dis.
2010 May 7.
Abstract |
Quantifying the treatment efficacy of reverse transcriptase inhibitors: new
analyses of clinical
data based on within-host modeling.
Breban R, Napravnik S, Kahn J, Blower S.
BMC Public Health.
2009 Nov 18;9 Suppl 1:S11.
Abstract |
Effects of nucleoside reverse transcriptase inhibitor backbone on the
efficacy of first-line
boosted highly active antiretroviral therapy based on protease
inhibitors: meta-regression
analysis of 12 clinical trials in 5168 patients.
Hill A, Sawyer W.
HIV Med.
2009
Oct;10(9):527-35.
Abstract |
Initial therapy with nucleoside reverse transcriptase inhibitor-containing
regimens is more effective than with
regimens that spare them with no difference in short-term fat distribution:
Hippocampe-ANRS 121 Trial.
Duvivier C, Ghosn J, Assoumou L, Soulié C, et al
J Antimicrob Chemother. 2008 Jul
18.
Abstract
|
Triple nucleoside reverse transcriptase inhibitor- vs. nonnucleoside
reverse transcriptase
inhibitor-containing regimens as first-line therapy:
efficacy and durability in a prospective cohort
of French HIV-infected
patients.
Cuzin L, Pugliese P, Bugnon F, et al
HIV Med. 2005 Nov;6(6):388-95.
Abstract
|
Differential susceptibility of retroviruses to nucleoside analogues.
Rosenblum LL, Patton G,
Grigg AR et al.
Antivir Chem Chemother 2001 Mar;12(2):91-7
Abstract
|
Journal Papers, Abstracts, and Commentaries
Journal
Papers, Abstracts, and Commentaries
| |
Nucleoside reverse-transcriptase inhibitor cross-resistance
and outcomes from second-line antiretroviral therapy in the
public health approach: an observational analysis within the
randomised, open-label, EARNEST trial.
Paton NI, Kityo C, Thompson J, et al
Lancet HIV. 2017 May 8. pii:
S2352-3018(17)30065-6.
Abstract
FULL-TEXT
ARTICLE
Development and Customization of a Color-Coded Microbeads-Based
Assay for Drug Resistance in HIV-1 Reverse Transcriptase.
Gu L, Kawana-Tachikawa A, Shiino
T, et al
PLoS One.
2014 Oct 14;9(10):e109823
Paper
Low-Frequency HIV-1 Drug Resistance Mutations and Risk of
NNRTI-Based Antiretroviral
Treatment Failure: A Systematic Review and Pooled Analysis.
Li JZ, Paredes
R, Ribaudo HJ, et al
JAMA. 2011 Apr 6;305(13):1327-35.
Abstract |
A Novel Molecular Mechanism of Dual Resistance to NRTIs and
NNRTIs.
Nikolenko GN, Delviks-Frankenberry KA, Pathak VK.
J Virol.
2010 Mar 10.
Abstract |
Nucleoside and nucleotide analogs select in culture for
different patterns of drug resistance in human
immunodeficiency viruses 1 and 2.
Ntemgwa ML, Toni TD, Brenner BG,et al
Antimicrob Agents Chemother.
2008 Dec 8.
Abstract
|
Prevalence of complete resistance to at least two classes of
antiretroviral drugs in treated
HIV-1-infected patients: A French
nationwide study.
Masquelier B, Costagliola D, Schmuck A .
J Med Virol. 2005 Aug;76(4):441-6.
Abstract
|
FULL-TEXT ARTICLE
Establishment of new transmissible and drug-sensitive human
immunodeficiency
virus type 1 wild
types due to transmission of
nucleoside analogue-resistant
virus.
de Ronde A, van
Dooren M, van Der Hoek
Virol
2001 Jan;75(2):595-602
Paper
|
|
|
Ribavirin
Journal Papers, Abstracts, and Commentaries
Journal Papers, Abstracts, and Commentaries
| |
FULL-TEXT
ARTICLE
Development and Customization of a Color-Coded Microbeads-Based
Assay for Drug Resistance in HIV-1 Reverse Transcriptase.
Gu L, Kawana-Tachikawa A, Shiino
T, et al
PLoS One.
2014 Oct 14;9(10):e109823
Paper
Evaluation of HIV-1 Ambiguous Nucleotide Frequency
during Antiretroviral Treatment Interruption.
Li JZ, Christensen JA, Wang H, et al
J Acquir Immune Defic Syndr.
2012 Jun 22
Abstract
FULL-TEXT
ARTICLE
Measuring Enzymatic HIV-1 Susceptibility to Two Reverse
Transcriptase Inhibitors as a Rapid and Simple
Approach to HIV-1 Drug-Resistance Testing.
Hoffmann D, Garcia AD, Harrigan PR,
et al
PLoS One.
2011;6(7):e22019.
Paper
Development and validation of a liquid chromatographic/tandem mass
spectrometric assay for the
quantitation of nucleoside HIV reverse transcriptase inhibitors in
biological matrices.
Compain S, Schlemmer D, Levi M,et al
Mass Spectrom. 2005 Jan 11;40(1):9-18
Abstract |
|
|
Journal Papers, Abstracts, and Commentaries
|
|
Journal Papers, Abstracts, and Commentaries
|
|
Nucleoside/Nucleotide Reverse Transcriptase Inhibitors |
|
New
and Noteworthy
Database
of ARV Drug Interactions
Documents identified with this icon are in Portable Document Format (PDF)
and require the
Adobe
Acrobat Reader
